A small early-stage study testing psilocybin (the active compound in magic mushrooms) as a treatment for OCD (obsessive-compulsive disorder, a condition marked by unwanted repetitive thoughts and behaviors) will report that it's safe and shows early signs of working. That positive result will be enough to get at least one new, larger OCD trial officially registered and launched within about three months. This matters because OCD is hard to treat and has few good options.
Feasibility studies that survive to publication almost always report a positive safety signal; OCD is an underserved indication ready for expansion.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →